Trading
(Post 231/Yr 4 wk 17)Company Report:ARK Investment Management Daily Trades 12/8/2020
By Sonicericsg  •  January 9, 2021
12/8/2020 Castle Biosciences Inc Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company has two market proprietary products, DecisionDx-Melanoma and DecisionDx-UM, and have two active proprietary products in development DecisionDx-UM and DecisionDx-Melanoma. The Company is developing a treatment plan for certain cancers using clinical and pathology factors. Its lead product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP), a test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. Day Range Brought:55.00-57.02 Novartis AG Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism....
Read the full article
By Sonicericsg
Hi everyone, I'm soniceric, my real name is of course not soniceric, it's just Ericsson :) The reason I name this blog as soniceric is a word play on the brand of "sony Ericsson" hence soniceric(geddit?) I am currently a 22 years old nsf who is about to ord soon and receiving a paltry ns allowance of $800 per month. To date, I have managed to save more than 10k and have already use the money for various purpose(emergency fund, peer to peer lending,posb invest saving and stocks, trading etc).
LEAVE A COMMENT
LEAVE A COMMENT

Your email address will not be published.

*

Your Email Address will not be published
*

Read More Articles
More from thefinance